GSK plc stock (GB0009252882): Fresh 13F filing and annual report keep big pharma in focus

GSK plc has filed a new Form 13F detailing institutional holdings and recently published its Annual Report for 2025, keeping the UK pharma heavyweight on the radar of global and US investors amid a solid share-price performance over the past year.

GSK plc has attracted renewed investor attention after a recent Form 13F filing disclosed institutional holdings alongside the publication of its Annual Report for the year ended December 31, 2025, giving markets fresh insight into the pharmaceutical group’s ownership structure and strategic priorities, according to Stock Titan as of 05/09/2026 and an overview on Ad-hoc-news as of 04/28/2026.

As of: 05/15/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GSK
• Sector/industry: Pharmaceuticals and vaccines
• Headquarters/country: Brentford, United Kingdom
• Core markets: Europe, United States, international pharmaceuticals and vaccines markets
• Key revenue drivers: Prescription medicines, specialty pharma, vaccines and consumer health royalty streams
• Home exchange/listing venue: London Stock Exchange (ticker: GSK), NYSE (ticker: GSK, ADR)
• Trading currency: GBP in London, USD for the NYSE ADR

GSK plc: core business model

GSK plc is a global pharmaceutical group focused on prescription medicines and vaccines, with a portfolio that spans infectious diseases, respiratory conditions, HIV and immunology. The company has positioned itself as a pure-play biopharma business after separating its consumer health arm in previous years, a shift aimed at sharpening strategic focus on higher-margin, innovation-driven therapeutics, as outlined in the 2025 Annual Financial Report referenced by Ad-hoc-news as of 04/28/2026.

The group’s research and development activities are organized around several therapeutic areas, including vaccines and specialty medicines, with a multi-year pipeline of clinical programs at different stages. Management emphasizes a data- and genetics-led R&D approach to improve success rates and target areas of high unmet medical need, a theme repeatedly highlighted in company reporting and investor materials released alongside the 2025 annual disclosures, according to Ad-hoc-news as of 04/28/2026.

GSK generates revenue primarily by developing, manufacturing and commercializing medicines and vaccines, while also benefiting from certain royalty and milestone income related to legacy consumer health and partnered assets. The business model is capital intensive and heavily regulated, with substantial upfront R&D investments that may take years to translate into approved products and cash flows, reflecting the risk-reward profile typical of large-cap pharmaceutical peers reviewed by major financial portals such as MarketBeat as of 05/10/2026.

Main revenue and product drivers for GSK plc

GSK’s revenue base is anchored in a portfolio of established pharmaceuticals and vaccines that includes treatments in respiratory, infectious diseases and HIV. While individual product names and contributions vary across regions, management continues to stress the importance of scaling newer specialty medicines and next-generation vaccines to offset patent expiries and generic competition, as discussed in commentary linked to the 2025 Annual Report summarized by Ad-hoc-news as of 04/28/2026.

Growth also depends on geographic diversification. The United States remains a critical market for high-value specialty therapies and vaccines, providing a significant share of group revenues due to higher pricing levels and broad insurance coverage. At the same time, GSK has a strong presence in Europe and various international markets, which helps balance exposure to individual healthcare systems but also adds complexity in terms of pricing, reimbursement and regulatory interactions, as reflected in market analyses compiled by MarketBeat as of 05/10/2026.

In recent quarters, revenue growth has been supported by demand for key vaccines and specialty products, while legacy primary care brands face competitive pressures. Earnings data cited by financial services show that GSK reported earnings per share for a recent quarter that modestly exceeded consensus expectations, with revenue up low- to mid-single digits year over year, according to figures summarized on MarketBeat as of 02/05/2026; these numbers relate to a specific quarter and reflect performance in that reporting period only.

Institutional interest and the latest 13F filing

The latest Form 13F filing provides a snapshot of certain institutional holdings in GSK as of the filing date, illustrating how professional investors are positioned in the stock. According to the document summary, the filing reports 13 disclosed positions with an aggregate market value of approximately 599.15 million US dollars, with the information table detailing individual securities and quantities, as reported by Stock Titan as of 05/09/2026.

The form was signed by Victoria Whyte as authorized signatory on May 9, 2026, underscoring that it reflects a dated regulatory disclosure rather than real-time positions. For US-based investors who track institutional participation as an indicator of market confidence and liquidity, such filings can provide context on how large holders allocate capital across global pharmaceutical names, though they do not reveal the full universe of shareholders or intraperiod trading activity, as highlighted by the same summary on Stock Titan as of 05/09/2026.

Beyond the 13F filing, insider and executive share transactions can also influence sentiment. Recent coverage noted that GSK executives acquired shares under a company reward plan, signaling alignment between management and shareholders, though the volumes involved are typically small relative to total shares outstanding, according to transaction summaries on TipRanks as of 04/22/2026. Such moves are often pre-planned and structured, and therefore should be interpreted in the broader context of compensation schemes.

Share-price performance and valuation context

GSK shares have shown notable strength over the past year on the London market. Historical price data indicate that the stock has gained more than 30% over a 12?month period, with the price moving within a 52?week range of roughly 1,315 pence to 2,282 pence, highlighting a sizable recovery from lower levels, according to figures compiled by Investing.com as of 05/10/2026.

Daily trading data show episodes of pronounced short-term volatility. On one recent trading day, for example, GSK closed at around 1,462.50 pence with a gain of about 4.69% and volume above 11 million shares, underscoring how news flow and sector dynamics can trigger rapid price swings, as reflected in the same data set from Investing.com as of 05/10/2026. Such moves can be relevant for short-term traders while long-term investors may focus more on multi-year trends.

In terms of valuation, GSK currently trades at a price-to-earnings ratio that is markedly lower than that of some high-growth peers. MarketBeat data indicate a P/E ratio in the low-teens, compared with an average market multiple that is substantially higher, suggesting that the stock is valued more like a mature pharma name than a growth stock, according to metrics published by MarketBeat as of 05/10/2026. Whether this represents a discount or a reflection of risk is a matter for investors’ own analysis.

Signals from the 2025 Annual Report

The 2025 Annual Financial Report provides detailed insight into GSK’s performance for the year ended December 31, 2025, including revenue, earnings, cash flow and balance-sheet metrics. While the full document is extensive, coverage summarizing its publication notes that it outlines strategic priorities such as continued investment in the vaccines pipeline, optimization of the commercial footprint and disciplined capital allocation, according to an overview by Ad-hoc-news as of 04/28/2026.

The report also emphasizes GSK’s approach to managing legal and regulatory risks, an important consideration given ongoing sector-wide scrutiny of drug pricing, product safety and marketing practices. Recent news flow in the broader pharma space has included FDA-related developments around neurological and autism treatments, reflecting the high bar regulators set for new therapies, though these particular developments were not directly tied to GSK’s portfolio, as contextualized by sector commentary on MarketScreener as of 10/31/2025.

From a financial standpoint, the Annual Report discusses how earnings and cash generation in 2025 supported dividends, reinvestment into R&D and potential debt reduction, although precise numbers must be taken from the company’s own audited statements for that reporting year. For investors, the document serves as a key reference to assess balance-sheet flexibility, exposure to patent cliffs and the funding of future growth initiatives as of the end of 2025, as highlighted in summary references on Ad-hoc-news as of 04/28/2026.

Why GSK plc matters for US investors

For US investors, GSK is accessible via sponsored American Depositary Receipts listed on the New York Stock Exchange, offering exposure to a diversified European pharma player without the need to trade on foreign exchanges. This structure can simplify custody, settlement and reporting for US-based portfolios, while still providing participation in the company’s global earnings and dividends, as noted by data providers following the NYSE listing such as MarketBeat as of 05/10/2026.

Strategically, GSK’s strong presence in the US pharmaceutical and vaccines market means that its fortunes are partly tied to US healthcare spending, reimbursement trends and regulatory decisions. Developments such as changes in Medicare negotiations, drug pricing frameworks or vaccine recommendations can influence revenue trajectories, making the stock a way to express a view on the broader US healthcare environment through a non-US domiciled issuer, a theme often discussed in sector-wide analyses on Investing.com as of 05/10/2026.

GSK also plays a role in global health initiatives and partnerships, which can shape its reputation and long-term demand, especially in vaccines and infectious disease management. These activities may not always translate directly into near-term profits but can support durable relationships with governments, multilateral organizations and health systems, factors that long-horizon US investors frequently consider when evaluating large pharmaceutical names, based on commentary gathered across major financial news outlets over the past year.

Conclusion

GSK plc’s recent 13F filing and the publication of its 2025 Annual Report provide fresh transparency on both its shareholder base and strategic direction, while a solid share-price performance and a valuation in the low-teens earnings multiple keep the stock firmly in focus for global investors. The company’s reliance on a broad portfolio of vaccines and specialty medicines, combined with meaningful exposure to the US healthcare system, offers diversification but also entails regulatory and competitive risks. For US-based market participants following large-cap pharma, GSK represents a sizable, innovation-driven player whose future returns will depend on pipeline execution, policy developments and the ability to balance shareholder distributions with sustained investment in research and development.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.